Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia
Authors:
- 1 September 2001
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (6) , 609-611
Abstract
We report a 62-year-old male who underwent non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) because of his life-threatening severe pancytopenia due to refractory Waldenström's macroglobulinemia. This therapy was performed safely and he made a marked recovery from his cytopenia that had not been improved with any other therapy. Bone marrow aspirates showed post-transplant mixed chimerism during engraftment, and became completely donor-derived after a series of GVHD symptoms, without subsequent donor lymphocyte infusion. Our results suggest that non-myeloablative allogeneic PBSCT could be a good alternative for patients suffering from multi-drug resistant Waldenström's macroglobulinemia. Bone Marrow Transplantation (2001) 28, 609–611.Keywords
This publication has 7 references indexed in Scilit:
- Mini-allografts: ongoing trials in humansBone Marrow Transplantation, 2000
- Waldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementJournal of Clinical Oncology, 2000
- Autologous peripheral blood stem cell transplantation for Waldenstrom’s macroglobulinemiaBone Marrow Transplantation, 1999
- Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemiaBritish Journal of Haematology, 1999
- High‐dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemiaBritish Journal of Haematology, 1999
- Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemiaBone Marrow Transplantation, 1999
- Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.Journal of Clinical Oncology, 1998